

2 Figure S1A Effect of interventions in SN and CG on TER forest plot




Figure S1B Effect of interventions in SN and CG on WHT forest plot

3

5

	Expe	rimen	tal	С	ontrol			Mean Difference			Mea	n Differ	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI			IV. F	ixed, 95	5% CI	
Cui XX, 2022	4.9	3.15	220	12.86	5.89	220	31.2%	-7.96 [-8.84, -7.08]		-				
He YH, 2018	4.9	3.15	40	12.86	5.89	40	5.7%	-7.96 [-10.03, -5.89]	_		-8			
Ye XS, 2020	4.11	1.42	40	12.11	1.41	40	63.2%	-8.00 [-8.62, -7.38]						
Total (95% CI)			300			300	100.0%	-7.99 [-8.48, -7.49]		٠				
Heterogeneity: Chi ² = Test for overall effect:					ó			a	-10 Favours		-5 periment	0 tal] Far	5 vours [co	10 ontrol]




Figure S1D Effect of interventions in SN and CG on PDT forest plot

8


9

	Experim	ental	Contr	ol		Risk Ratio			Risk Ratio	1	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-	H, Fixed, 95	% CI	
He YH, 2018	5	40	10	40	29.4%	0.50 [0.19, 1.33]		0			
Jia CL, 2021	6	33	18	33	52.9%	0.33 [0.15, 0.73]		-	_		
Zeng Y, 2020	2	30	6	30	17.6%	0.33 [0.07, 1.52]		8			
Total (95% CI)		103		103	100.0%	0.38 [0.22, 0.67]		<	▶		
Total events	13		34								
Heterogeneity: Chi ² =	0.44, $df = 2$	P = 0.1	80); $I^2 = 0$	1%			0.04	01		10	100
Test for overall effect:	Z = 3.32 (F	P = 0.000	09)				0.01 Favo	0.1 urs [experime	ental] Favo	10 ours [control]	100

Figure S1E Effect of interventions in SN and CG on AEs forest plot

	Exp	erimen	tal		ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.1.1 <6 hours									
Cui XX, 2022	1.52	0.21	220	2.67	0.32	220	56.8%	-1.15 [-1.20, -1.10]	
He YH, 2018	6.35	2.05	40	7.67	1.23	40	0.3%	-1.32 [-2.06, -0.58]	
Ye XS, 2020	1.52	0.21	40	2.67	0.32	40	10.3%	-1.15 [-1.27, -1.03]	7
Subtotal (95% CI)			300			300	67.3%	-1.15 [-1.20, -1.10]	•
Heterogeneity: Chi ² =	0.20, df :	= 2 (P =	0.90);	$I^2 = 0\%$					
Test for overall effect:	Z = 48.5	57 (P < 0	0.00001)					
1.1.2 6-48hours									
Jia CL, 2021	6.02	0.57	33	7.53	0.6	33	1.8%	-1.51 [-1.79, -1.23]	
Liu HM, 2023	5.44	0.91	45	5.92	0.13	45	2.0%	-0.48 [-0.75, -0.21]	
Zeng Y, 2020	3.1	0.803	30	3.73	1.172	30		-0.63 [-1.14, -0.12]	
Subtotal (95% CI)			108			108	4.4%	-0.93 [-1.11, -0.74]	◆
Heterogeneity: Chi2 =	28.33, df	f = 2 (P	< 0.000	001); l ²	= 93%				***
Test for overall effect:	Z = 9.99	(P < 0.	00001)						
1.1.3 3 days									
Jia CL, 2021	3.34	0.44	33	5.96	0.68	33	1.9%	-2.62 [-2.90, -2.34]	
Wang W, 2018	3.52	0.48	30	4.1	0.82	30		-0.58 [-0.92, -0.24]	× —
Zeng HM, 2019	3.88	2.151	40	4.9	2.329	40		-1.02 [-2.00, -0.04]	_ ·
Subtotal (95% CI)			103			103	3.3%	-1.77 [-1.98, -1.56]	•
Heterogeneity: Chi ² =	85.64, dt	f = 2 (P	< 0.000	001); l ²	= 98%				
Test for overall effect:	Z = 16.5	8 (P < 0	0.00001)					
1.1.4 4days									
Jia CL, 2021	1.32	0.52	33	2.41	0.43	33		-1.09 [-1.32, -0.86]	
Wang W, 2018	3.28	0.7	30	4.36	1.02	30		-1.08 [-1.52, -0.64]	10 <u>-00-00</u>
Zeng HM, 2019	3.43	1.933	40	4.4	2.251	40		-0.97 [-1.89, -0.05]	
Subtotal (95% CI)		0.15	103			103	3.7%	-1.08 [-1.28, -0.88]	~
Heterogeneity: Chi ² = Test for overall effect:									
1.1.5 5 days									
Wang W, 2018	3.12	0.86	30	4.38	1	30	0.7%	-1.26 [-1.73, -0.79]	
Zeng HM, 2019	2.93	1.76	40	3.93	1.845	40		-1.00 [-1.79, -0.21]	1
Subtotal (95% CI)			70			70	0.9%	-1.19 [-1.60, -0.79]	•
Heterogeneity: Chi ² =	0.31, df	= 1 (P =	0.58);	$I^2 = 0\%$					
Test for overall effect:	Z = 5.76	6 (P < 0.	00001)						
1.1.6 7-14days									
Guo D, 2021	3.52	0.15	30	5.09	0.19	30		-1.57 [-1.66, -1.48]	
Wang W, 2018 Subtotal (95% CI)	2	0.37	30 60	3.64	0.96	30 60		-1.64 [-2.01, -1.27] -1.57 [-1.66, -1.49]	•
Heterogeneity: Chi ² =	0 13 df	= 1 (P =		I ² = 0%		-			
Test for overall effect:									
Total (95% CI)			744			744	100.0%	-1.25 [-1.28, -1.21]	•
Heterogeneity: Chi ² =	227.72.	df = 15	(P < 0.0	00001):	l ² = 939				
					70	000			-2 -1 0 1 2
Test for overall effect:	Z = 04.U	11 (1 - 1							Favours [experimental] Favours [control]

Figure S2A Subgroup analysis of VAS on different measurement times for CG



14 Figure S2B Subgroup analysis of VAS on different treatments for CG




Figure S2C Subgroup analysis of VAS on different acupoints for CG




Figure S3A Statistical analyses of interventions in SN and CG on VAS





Figure S3B Statistical analyses of interventions in SN and CG on TER



23

22 Figure S3C Statistical analyses of interventions in SN and CG on WHT





Figure S3D Statistical analyses of interventions in SN and CG on PRT



27

Figure S3E Statistical analyses of interventions in SN and CG on PDT




Figure S3F Statistical analyses of interventions in SN and CG on AEs



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 1-2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 2-4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Page 4
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Appendices
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 5
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 5
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 5
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 5-6
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 6
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 19
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 6
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Page 6
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Page 6
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Page 6
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Page 6
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Page 6
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page 6



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 6-7
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	N/A
Study characteristics	17	Cite each included study and present its characteristics.	Page 7
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Page 7
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Page 20-21
Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Page 8-9
syntheses	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Page8-11
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Page 9-10
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Page 10-11
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Page 8
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Page 11
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 11-13
	23b	Discuss any limitations of the evidence included in the review.	Page 13
	23c	Discuss any limitations of the review processes used.	Page 13
	23d	Discuss implications of the results for practice, policy, and future research.	Page 13
OTHER INFORMA	TION		
Registration and	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 4
protocol	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 4
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	
Competing interests	26	Declare any competing interests of review authors.	Page 13
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

Author(s): Huang QQ

Date: 2023-08-28

Question: VAS for Postoperative hemorrhoid pain

Settings: SN vs CG

			Quality as	sessment				No of		Effect		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	VAS	Control	Relative (95%	Absolute	Quality	Importance
				\ <u>\</u>	S (Bottor indicate	d by lower values)			CI)			
	1	1	ı	V F	To (better indicate	u by lower values)		<u> </u>			1	T
9	randomised	serious ¹	no serious	no serious	no serious	none	508	508	-	MD 1.1 lower (1.31 to	⊕⊕⊕О	CRITICAL
	trials		inconsistency ²	indirectness	imprecision					0.89 lower)	MODERATE	
				measuri	ng time (Better in	dicated by lower val	ues)					
9	randomised	serious ¹	no serious	no serious	no serious	none	744	744	-	MD 1.25 lower (1.28 to	⊕⊕⊕О	CRITICAL
	trials		inconsistency	indirectness	imprecision					1.21 lower)	MODERATE	
				measuring tin	ne - 0-6 hours (Bet	ter indicated by low	er va	lues)				
3	randomised	serious ¹	no serious	no serious	no serious	none	300	300	-	MD 1.15 lower (1.2 to 1.1	⊕⊕⊕О	IMPORTANT
	trials		inconsistency	indirectness	imprecision					lower)	MODERATE	
				measuring tim	ne - 6-48hours (Be	tter indicated by low	er va	lues)				
3	randomised	serious ¹	serious ³	no serious	serious ⁴	none	108	108	-	MD 0.93 lower (1.11 to	⊕000	IMPORTANT
	trials			indirectness						0.74 lower)	VERY LOW	
				measuring ti	ime - 3 days (Bette	er indicated by lowe	r valu	ies)				
3	randomised	serious ¹	no serious	no serious	serious ⁴	none	103	103	-	MD 1.77 lower (1.98 to	⊕⊕OO	IMPORTANT

	trials		inconsistency ³	indirectness						1.56 lower)	LOW	
				measuring t	time - 4days (Bette	er indicated by lowe	r valu	es)			•	
3	randomised	serious ¹	no serious	no serious	serious ⁴	none	103	103	-	MD 1.08 lower (1.28 to	⊕⊕ОО	IMPORTANT
	trials		inconsistency	indirectness						0.88 lower)	LOW	
				measuring t	ime - 5 days (Bette	er indicated by lowe	r valu	es)				
2	randomised	serious ¹	no serious	no serious	serious ⁴	none	70	70	-	MD 1.19 lower (1.6 to	⊕⊕00	IMPORTANT
	trials		inconsistency	indirectness						0.79 lower)	LOW	
				measuring tir	ne - 7-14days (Bet	ter indicated by low	er val	ues)			•	
2	randomised	serious ¹	no serious	no serious	no serious	none	60	60	-	MD 1.57 lower (1.66 to	⊕⊕⊕О	IMPORTANT
	trials		inconsistency	indirectness	imprecision					1.49 lower)	MODERATE	
				Different treatment	t modalities for CO	6 (Better indicated b	y low	er values	\$)			
9	randomised	serious ¹	serious ³	no serious	no serious	none	508	508	-	MD 1.22 lower (1.26 to	⊕⊕00	IMPORTANT
	trials			indirectness	imprecision					1.18 lower)	LOW	
				Western med	ical therapies (Bet	ter indicated by low	er va	ues)				
5	randomised	serious ¹	serious ³	no serious	no serious	none	195	195	-	MD 1.05 lower (1.15 to	⊕⊕00	IMPORTANT
	trials			indirectness	imprecision					0.94 lower)	LOW	
				Chinese med	ical therapies (Bet	ter indicated by low	er val	ues)				
2	randomised	serious ¹	no serious	no serious	serious ⁴	none	63	63	-	MD 1.09 lower (1.29 to	⊕⊕00	IMPORTANT
	trials		inconsistency	indirectness						0.88 lower)	LOW	
				Nursing routin	e interventions (B	etter indicated by lo	wer v	alues)				
2	randomised	serious ¹	serious ³	no serious	no serious	none	250	250	-	MD 1.26 lower (1.3 to	⊕⊕ОО	IMPORTANT
	trials			indirectness	imprecision					1.21 lower)	LOW	
				acupunct	ture point (Better i	ndicated by lower v	alues					
7	randomised	serious ¹	serious ³	no serious	no serious	none	438	438	-	MD 1.13 lower (1.17 to	⊕⊕00	IMPORTANT
		•	•	•	•					•		

	trials			indirectness	imprecision					1.08 lower)	LOW	
				acupuncture	e point - EB (Bette	r indicated by lower	r valu	es)				
2	randomised	serious ¹	no serious	no serious	serious ⁴	none	63	63	-	MD 1.09 lower (1.29 to	⊕⊕00	IMPORTANT
	trials		inconsistency	indirectness						0.88 lower)	LOW	
				acupuncture	point - HG (Bette	r indicated by lower	r valu	es)				
2	randomised	serious ¹	serious ³	no serious	no serious	none	250	250	-	MD 1.14 lower (1.2 to	⊕⊕00	IMPORTANT
	trials			indirectness	imprecision					1.09 lower)	LOW	
				acupuncture	point - SM (Bette	r indicated by lower	r valu	es)				
3	randomised	serious ²	serious ³	no serious	no serious	none	125	125	-	MD 1.05 lower (1.16 to	⊕⊕ОО	IMPORTANT
	trials			indirectness	imprecision					0.94 lower)	LOW	

¹ Lack of clarity in allocation concealment

Author(s): Huang QQ

Date: 2023-08-28

Question: WHT for Postoperative hemorrhoid pain

Settings: SN vs CG

			Quality asses	sment				lo of tients		Effect	Ouglitus	Immontono
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	WHT	Control	Relative (95% CI)	Absolute	Quanty	Importance

² Heterogeneity is large, but can be explained

³ High heterogeneity and unexplained

⁴ Small sample size, large confidence intervals

				WHT (Be	etter indicate	ed by lower values)						
3	randomised	serious ¹	no serious	no serious	serious ²	none	93	93	-	MD 2.55 lower (3.02 to 2.09	⊕⊕00	IMPORTANT
	trials		inconsistency	indirectness						lower)	LOW	

¹ Blindness and allocation hide ambiguity

Author(s): Huang QQ
Date: 2023-08-28

Question: TER for Postoperative hemorrhoid pain

Settings: SN vs CG

Bibliography: SN versus CG for Postoperative hemorrhoid pain. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

			Quality as	sessment			No of p	oatients		Effect		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	TER	Control	Relative (95% CI)	Absolute	Quality	Importance
						TER						
4	randomised	serious	no serious	no serious	no serious	none	152/156	129/156	RR 1.18 (1.09	149 more per 1000 (from	⊕⊕⊕О	IMPORTANT
	trials		inconsistency	indirectness	imprecision		(97.4%)	(82.7%)	to 1.27)	74 more to 223 more)	MODERATE	
								04.40/		151 more per 1000 (from		
								84.1%		76 more to 227 more)		

Author(s): Huang QQ

Date: 2023-08-28

Question: Should AEs be used for Postoperative hemorrhoid pain?

Settings: SN vs CG

² Small sample size, large confidence intervals

			Quality asse	ssment			No of p	atients		Effect		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	AEs	Control	Relative (95% CI)	Absolute	Quality	Importance
						AEs						
3	randomised	serious	no serious	no serious	serious ¹	none	13/103	34/103	RR 0.38 (0.22	205 fewer per 1000 (from 109	⊕⊕00	IMPORTANT
	trials		inconsistency	indirectness			(12.6%)	(33%)	to 0.67)	fewer to 257 fewer)	LOW	
								250/		155 fewer per 1000 (from 82		
								25%		fewer to 195 fewer)		

¹ Small sample size, large confidence intervals

Author(s): Huang QQ

Date: 2023-08-28

Question: Should PRT be used for Postoperative hemorrhoid pain?

Settings: SN vs CG

Quality assessment							No of patients		Effect				
No stud		Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	PRT Control		Relative (95% CI)	Absolute	Quality	Importance
	PRT (Better indicated by lower values)												
3		randomised trials	serious ¹			no serious imprecision	none	300	300	-	MD 7.99 lower (8.48 to 7.49 lower)	⊕⊕⊕O MODERATE	IMPORTANT

¹ Blindness and allocation hide ambiguity

Author(s): Huang QQ

Date: 2023-08-28

Question: Should PDT be used for Postoperative hemorrhoid pain?

Settings: SN vs CG

Quality assessment						No of patients			Effect	Quality		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	PDT Control Relative (95% CI)			Absolute	Quanty	Importance
PDT (Better indicated by lower values)												
2	randomised	serious ¹	no serious	no serious	serious ²	none	260	260	-	MD 0 higher (14.17 to 24.31	⊕⊕00	IMPORTANT
	trials		inconsistency	indirectness						higher)	LOW	

¹ Blindness and allocation hide ambiguity

² Small sample size, large confidence intervals

PubMed

(((("Pain, Postoperative"[Mesh]) OR OR OR (Pain, Post-surgical[Title/Abstract])) (Post surgical Pain[Title/Abstract])) OR (Pain, Post-operative[Title/Abstract])) OR operative[Title/Abstract])) OR (Pain, Post (Postsurgical Pain[Title/Abstract])) OR (Pain, Postsurgical[Title/Abstract])) Pain[Title/Abstract])) (Post-operative OR (Post operative Pain[Title/Abstract])) OR (Post-operative Pains[Title/Abstract])) OR (Postoperative Pain[Title/Abstract])) OR (Postoperative Pain, Chronic[Title/Abstract])) OR (Pain, Chronic Postoperative[Title/Abstract])) OR (Chronic Postoperative Pain[Title/Abstract])) OR (Chronic Post-surgical Pain[Title/Abstract])) OR (Chronic Post surgical Pain[Title/Abstract])) OR (Pain, Chronic Post-surgical[Title/Abstract])) OR (Post-surgical Pain, Chronic[Title/Abstract])) OR (Chronic Postsurgical Pain[Title/Abstract])) OR (Chronic Postsurgical Pains[Title/Abstract])) OR (Pain, Chronic Postsurgical[Title/Abstract])) OR (Postsurgical Pain, Chronic[Title/Abstract])) OR Postsurgical (Persistent Pain[Title/Abstract])) OR (Pain, Persistent Postsurgical[Title/Abstract])) OR (Postsurgical Pain, Persistent[Title/Abstract])) OR (Post-operative

OR Pain, Chronic[Title/Abstract])) (Pain, Chronic Post-operative[Title/Abstract])) OR (Post operative Pain, OR Chronic[Title/Abstract])) (Chronic Post-operative Pain[Title/Abstract])) OR (Chronic Post operative Pain[Title/Abstract])) OR (Postoperative Pain, Acute[Title/Abstract])) OR (Pain, Acute Postoperative[Title/Abstract])) OR (Acute Postoperative Pain[Title/Abstract])) OR (Acute Post-operative Pain[Title/Abstract])) OR (Acute Post operative Pain[Title/Abstract])) OR (Post-operative Pain, Acute[Title/Abstract])) OR (Pain, Acute Post-operative[Title/Abstract])) OR (Post operative Pain, Acute[Title/Abstract]))) **AND** (("Hemorrhoids"[Mesh]) OR (((external hemorrhoid[Title/Abstract]) OR (internal hemorrhoid[Title/Abstract])) OR (mixed hemorrhoids[Title/Abstract]))) AND (("Acupuncture, Ear"[Mesh]) OR button[Title/Abstract]) OR (press needle[Title/Abstract])) OR (bell peg[Title/Abstract])) OR (ear pin[Title/Abstract])) OR (Ear acupuncture[Title/Abstract])) OR (Acupunctures, Ear[Title/Abstract])) OR (Ear Acupunctures[Title/Abstract])) OR (Auricular Acupuncture[Title/Abstract])) OR (Acupuncture, Auricular[Title/Abstract])) OR (Acupunctures, Auricular[Title/Abstract])) OR Acupunctures[Title/Abstract])) (Auricular OR (hypodermic needle[Title/Abstract])) OR (intradermal needle[Title/Abstract])) OR

 (countersunk
 (of needle[Title/Abstract])))
 OR

 (Acupuncture[Title/Abstract])))
 AND (("randomized controlled trial"[Publication Type] OR "randomized"[Title/Abstract] OR

 "placebo"[Title/Abstract] OR "RCTs"[Title/Abstract]))

EMBASE

Embase session results (16 Aug 2023)

No.	Query	Results
#13	#9 AND #10 AND #11 AND #12	7
#12	#4 OR #8	1430831
#11	#3 OR #5	101503
#10	#2 OR #6	40412
#9	#1 OR #7	12941

No. Query Results

randomized:ti,ab,kw OR placebo:ti,ab,kw OR rcts:ti,ab,kw 1197110
OR 'controlled trial, randomized':ti,ab,kw OR 'randomised controlled study':ti,ab,kw OR 'randomised controlled trial':ti,ab,kw OR 'randomized controlled study':ti,ab,kw OR 'trial, randomized controlled':ti,ab,kw OR 'randomized controlled trial':ti,ab,kw

- 'anus haemorrhoid':ti,ab,kw OR 'haemorrhoid':ti,ab,kw OR 6128

 'hemorrhoid syndrome':ti,ab,kw OR 'hemorrhoids':ti,ab,kw

 OR 'internal hemorrhoid':ti,ab,kw OR 'external

 hemorrhoid':ti,ab,kw OR 'mixed hemorrhoids':ti,ab,kw
- 'snap button':ti,ab,kw OR 'press needle':ti,ab,kw OR 'bell #6 40255 peg':ti,ab,kw OR 'ear pin':ti,ab,kw OR 'acupunctures, ear':ti,ab,kw OR 'ear acupunctures':ti,ab,kw OR 'auricular acupuncture':ti,ab,kw OR 'acupuncture, auricular':ti,ab,kw OR 'acupunctures, auricular':ti,ab,kw OR 'auricular acupunctures':ti,ab,kw OR 'hypodermic needle':ti,ab,kw OR 'intradermal needle':ti,ab,kw OR (countersunk:ti,ab,kw AND 'of needle':ti,ab,kw) OR acupuncture:ti,ab,kw OR 'acupuncture, ear':ti,ab,kw 'acupuncture, OR

No. Query Results

earlobe':ti,ab,kw OR 'auriculo-acupuncture':ti,ab,kw OR 'auriculoacupuncture':ti,ab,kw OR 'auriculotherapy':ti,ab,kw OR 'ear acupuncture':ti,ab,kw OR 'earlobe acupuncture':ti,ab,kw

#5 'post-surgical pain':ti,ab,kw OR 'pain, post-surgical':ti,ab,kw 55274 OR surgical pain':ti,ab,kw OR 'post 'pain, post-operative':ti,ab,kw OR 'pain, post operative':ti,ab,kw OR 'postsurgical pain':ti,ab,kw OR 'pain, postsurgical':ti,ab,kw OR 'post-operative pain':ti,ab,kw OR operative pain':ti,ab,kw OR 'post-operative 'post pains':ti,ab,kw OR 'postoperative pain':ti,ab,kw OR 'postoperative pain, chronic':ti,ab,kw OR 'pain, chronic OR 'chronic postoperative':ti,ab,kw postoperative pain':ti,ab,kw OR 'chronic post-surgical pain':ti,ab,kw OR 'chronic post surgical pain':ti,ab,kw OR 'pain, chronic post-surgical':ti,ab,kw OR 'chronic postsurgical pains':ti,ab,kw OR 'pain, chronic postsurgical':ti,ab,kw OR 'post-surgical pain, chronic':ti,ab,kw OR 'chronic pain':ti,ab,kw 'postsurgical postsurgical OR pain,

No. Query Results

chronic':ti,ab,kw OR 'persistent postsurgical pain':ti,ab,kw OR 'pain, persistent postsurgical':ti,ab,kw OR 'postsurgical OR pain, persistent':ti,ab,kw 'post-operative pain, chronic':ti,ab,kw OR 'pain, chronic post-operative':ti,ab,kw OR 'post operative pain, chronic':ti,ab,kw OR 'chronic post-operative pain':ti,ab,kw OR 'chronic post operative pain':ti,ab,kw OR 'postoperative pain, acute':ti,ab,kw OR 'pain, acute postoperative':ti,ab,kw OR 'acute postoperative pain':ti,ab,kw OR 'acute post-operative pain':ti,ab,kw OR 'acute post operative pain':ti,ab,kw OR 'post-operative pain, acute':ti,ab,kw OR 'pain, acute post-operative':ti,ab,kw OR 'post operative pain, acute':ti,ab,kw

#4	'randomized controlled trial'/exp	781066
#3	'postoperative pain'/exp	89203
#2	'auricular acupuncture'/exp	806
#1	'hemorrhoid'/exp	11952

Web of Science

TS= ("Pain, Postoperative" OR "Post-surgical Pain" OR "Pain, Post-surgical" OR "Post surgical Pain" OR "Pain, Post-operative" OR "Pain, Post operative" OR "Postsurgical Pain" OR "Pain, Postsurgical" OR "Post-operative Pain" OR "Post operative Pain" OR "Post-operative Pains" OR "Postoperative Pain" OR "Postoperative Pain, Chronic" OR "Pain, Chronic Postoperative" OR "Chronic Postoperative Pain" OR "Chronic Post-surgical Pain" OR "Chronic Post surgical Pain" OR "Pain, Chronic Post-surgical "OR "Post-surgical Pain, Chronic" OR "Chronic Postsurgical Pain" OR "Chronic Postsurgical Pains" OR "Pain, Chronic OR Postsurgical" OR "Postsurgical Pain, Chronic" "Persistent Postsurgical Pain" OR "Pain, Persistent Postsurgical" OR "Postsurgical Pain, Persistent" OR "Post-operative Pain, Chronic" OR "Pain, Chronic Post-operative" OR "Post operative Pain, Chronic" OR "Chronic Post-operative Pain" OR "Chronic Post operative Pain" OR "Postoperative Pain, Acute" OR "Pain, Acute Postoperative" OR "Acute Postoperative Pain" OR "Acute Post-operative Pain" OR "Acute Post operative Pain" OR "Post-operative Pain, Acute" OR "Pain, Acute Post-operative" OR "Post operative Pain, Acute") **AND** OR "external hemorrhoid" TS=("Hemorrhoids" OR "internal hemorrhoid" OR "mixed hemorrhoids" OR "anus haemorrhoid" OR

"haemorrhoid" OR "hemorrhoid syndrome" OR "hemorrhoid") AND TS=
("Acupuncture, Ear" OR "snap button" OR "press needle" OR "bell peg"
OR "ear pin" OR "Ear acupuncture" OR "Acupunctures, Ear" OR "Ear
Acupunctures" OR "Auricular Acupuncture" OR "Acupuncture,
Auricular" OR "Acupunctures, Auricular" OR "Auricular Acupunctures"
OR "hypodermic needle" OR "intradermal needle" OR "countersunk of
needle" OR "Acupuncture") AND TS=("randomized controlled trial" OR
"randomized" OR "placebo" OR "RCTs")

CBM

21)

序号 检索表达式 命中文献数 "痔疮"[常用字段:智能] OR "混合痔"[常用字段:智能] OR "内 16) 痔"[常用字段:智能] OR "外痔"[常用字段:智能] OR "痔"[常用字段:智 能] 27511 17) "痔"[不加权:扩展] 21769 "揿针"[常用字段:智能] OR "皮内针"[常用字段:智能] OR "耳 18) 针"[常用字段:智能] OR "埋针"[常用字段:智能] 7367 19) "皮内针疗法"[不加权:扩展] 130 "疼痛, 手术后"[不加权:扩展] 20) 20909

"手术后疼痛"[常用字段:智能] OR "术后疼痛"[常用字段:智能]

- 22) "随机化"[常用字段:智能] OR "随机"[常用字段:智能] OR "随机分配"[常用字段:智能] OR "随机分组"[常用字段:智能] OR "抽签"[常用字段:智能] OR "随机试验"[常用字段:智能] 1903943
- 23) ((("随机对照试验"[不加权:扩展]) OR "随机分配"[不加权:扩展]) OR "随机对照试验(主题)"[不加权:扩展]) OR "随机过程"[不加权:

∄ 展]		238208
24)	((#16) OR (#17))	27511
25)	((#18) OR (#19))	7367
26)	((#20) OR (#21))	69304
27)	((#23) OR (#22))	1904644
28)	((((#24) AND (#25))) AND (#26))	57
29)	(#28) AND (#27)	42

Wanfang

40日1

主题:(痔疮 OR 混合痔 OR 痔 OR 内痔 OR 外痔) and 题名或关键词:(术后疼痛 OR 手术后疼痛) and 主题:(揿针 OR 皮内针 OR 埋针 OR 耳针) and 摘要:(随机 OR 随机配对 OR 随机分组 OR 随机化 OR 随机过程 OR 抽签法 OR 随机试验)

VIP

(((((()题名或关键词=揿针 OR 题名或关键词=耳针) OR 题名或关键词=皮内针) OR 题名或关键词=埋针) AND ((((()ing=随机对照 OR 摘要=随机分组) OR 摘要=随机) OR 摘要=rct) OR 摘要=RCT) OR 摘要=随机化) OR 摘要=抽签) OR 摘要=随机过程)) AND ((((()题名或关键词=痔疮 OR 题名或关键词=haemorrhoid) OR 题名或关键词=haemorrhoids) OR 题名或关键词=痔核) OR 题名或关键词=痔疹 OR 题名或关键词=寿疹 OR 题名或关键词=寿) OR 题名或关键词=寿() OR 题名或关键词=手术后疼痛 OR 题名或关键词=手术后序编 OR 题名或关键词=手术后序编 OR 题名或关键词=并后序编)

CNKI

(主题: 揿针 + 方便揿针 + 耳穴揿针 + 清铃揿针 + 穴位揿针 + 督脉揿针 + 皮内针 + 埋针 + 耳针(精确))AND(主题: 痔疮 + 环状混合痔 + 混合痔 + 内痔 + 炎性痔疮 + 外痔 + 痔(精确))AND(篇关摘: 术后疼痛 + 手术后疼痛 + 术后(精确))AND(全文: 随机试验 + 随机 + 随机化 + 随机分组 + 随机分配 + 抽签(精确))